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 The term “microbiome” is used to describe the substantial number and diverse spectrum of microorganisms that inhabit 
the body. It plays an essential role in health conditions and diseases. Recent years have brought a further intensification 
of experimental studies on the impact of the microbiome on the human body, particularly with the aim of identifying 
and clarifying this impact. Many studies indicate that diet, lifestyle and drugs can affect the composition of the intestinal 
microflora, which, in turn, can modulate the development and progression of gastrointestinal tract tumors. It is suspected 
that the gut microbiome plays a significant role in the formation of gastrointestinal tumors. On the other hand, the role of 
the intestinal microflora in inhibiting the processes of oncogenesis suggests that this mechanism may be used to prevent 
and treat gastrointestinal cancer. Using probiotics to modify the microbiome may be beneficial in cancer therapy and may 
be used as a supportive treatment for classic cancer therapies such as chemotherapy, radiotherapy and surgical treatment. 
Intestinal microbiome analysis can be potentially used to develop non-invasive diagnostic tests. These tests could be 
useful as new protective markers for colorectal cancer, or as prognostic markers and predictive markers of response to 
treatment, especially immunotherapy.
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Introduction
The term “microbiome” is used to describe the substantial 
number and diverse spectrum of microorganisms that inhabit 
the body. It was suggested by Joshua Lederberg in 2001 to 
cover the entire population of commensal, symbiotic and 
pathogenic microorganisms. It has been established that with 
a mass of about 2 kg, the number of cells in the microbiome 
exceeds the number of cells that make up the healthy human 
body by 10 times. It plays an essential role in health conditions 
and diseases. Recent years have brought a further intensifica-
tion of experimental studies on the impact of the microbiome 
on the human body, particularly with the aim to identify and 
clarify this impact. 
Each part of the body is inhabited by a specific microbial 
population. The biggest and most heterogenous is that of the 
gut microbiota. This plays an important role in many diseases of 
the digestive and other systems, and exhibits a broad spectrum 
of actions, including effects on the immune system. Toll-like re-
ceptors (TLR) are sensors of infections caused by microorganisms 
and the microbiome, which play a major role in identifying the 
threat and initiating the inflammation and immune response. 
The intestinal microbiome stimulates both specific and non-
-specific immune mechanisms of the body. It is also involved 
in regulating immune responses. It affects the lymphoid tissue 
associated with the mucosal associated lymphoid tissue (MALT) 
and stimulates the synthesis of antibodies. Saprophytic bacteria 
of the gastrointestinal tract inhibit inflammation and affect the 
tightening of the intestinal epithelial barrier [1, 2].
It has been found that gastrointestinal cancers account for 
up to one third of all cancer diseases. A number of factors are 
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involved in oncogenesis – both extracellular, and intracellular, 
such as cellular membrane proteins and transmembrane pro-
teins localized in the cytosol or nucleus. Many studies indicate 
that diet, lifestyle and drugs can affect the composition of 
the intestinal microflora, which, in turn, can modulate the 
development and progression of gastrointestinal tract tumors. 
Therefore, it is suspected that the gut microbiome plays a si-
gnificant role in the formation of gastrointestinal tumors [3–5]. 
Intestinal bacteria stimulate the production of the tumor 
necrosis factor (TNF), which affects the activity of lymphocytes, 
cell metabolism, as well as the apoptosis of cancer cells. They 
can enhance the development and progression of gastro-
intestinal tumors by damaging DNA, activating oncogenic 
signaling pathways, producing tumor-stimulating metabolites 
such as secondary bile acids, and suppressing anti-tumor 
immunity [6].
It has been found that metabolites, such as the secondary 
fatty acids produced by some bacterial species, may promote 
the development of gastrointestinal tumors [7]. Experimental 
studies have identified microorganisms that can promote on-
cogenesis by increasing cell proliferation and the production 
of metabolites such as butyrate [8]. In contrast, the short-chain 
fatty acids (SCFA) produced by other species play a suppressing 
role in cell proliferation and cell apoptosis induction processes 
and are responsible for maintaining balance in anti-inflamma-
tory and pro-inflammatory reactions. They are characterized 
by the induction of T-regulatory cells (Treg) through free fatty 
acid receptors (GPR). To summarize, SCFA can suppress in-
flammatory processes and oncogenesis. In particular, a high 
concentration of butyric acid may inhibit oncogenesis. Cancer 
cells are characterized by a high rate of proliferation and the 
anti-tumor activity of butyric acid is based on inhibiting this 
proliferation.
Recently presented research results show that some bacte-
rial species produce metabolites such as secondary bile acids, 
and an increased concentration of these intensifies the deve-
lopment of gastrointestinal tumors due to their cytotoxicity [7].
The role of the intestinal microflora in inhibiting the pro-
cesses of oncogenesis suggests that this mechanism may be 
used in preventing and treating gastrointestinal cancer. 
The use of probiotics in preventing and treating 
cancerous diseases of the gastrointestinal tract
There is a connection between the intestinal microflora, its 
metabolic activity and the mode of nutrition. Combined with 
genetic predisposition, unfavorable environmental factors 
and bad eating habits may disturb the composition of the 
gastrointestinal microflora. Therefore, research is being carried 
out on the use of probiotics to modify the disbalance of gut 
microbiota [7]. Negative metabolic changes induced by inte-
stinal microorganisms can cause toxic oncogenic substances 
to form; these, in turn, may contribute to the development 
of cancer [9].
Administering probiotics increases the pool of beneficial 
intestinal microflora, and thus seems to create conditions for 
limiting changes in the intestines [10–12]. Researchers from 
Italy have presented a discussion of the results of studies 
which had been conducted on this problem [13]. Their re-
view suggests that probiotics may reduce the risk of cancer 
through a number of mechanisms, including the degradation 
of potential carcinogenic factors and the production of anti-
-cancer compounds.
Another literature review presents the results of research 
conducted on the impact of probiotics on the suppression of 
gastrointestinal and other cancers, and also on their mechani-
sms of action [14]. Other authors have also presented a review 
of literature on the mechanisms of probiotics in neoplastic 
diseases of the gastrointestinal tract [15]. Though numerous 
studies conducted on animal models can serve as evidence to 
the beneficial effects of probiotics in the prevention of neopla-
stic processes, it is necessary to conduct extensive clinical trials 
on humans to determine potential bacterial strains, dosages 
and schedules of administration depending on the types and 
stages of cancer development [16, 17].
The fecal microbiota transplant (FMT), which is a method 
used to cure specific diseases by reconstructing normal func-
tioning and the immune system, is also worth mentioning in 
this context. Its influence on the recipient’s immune system is 
complicated and unpredictable, so further investigation is ne-
cessary to answer numerous questions which still remain [18].
Among the modern drugs used in cancer therapy, much 
attention has been given to immunological drugs, i.e. to anti-
-CTLA4, anti-PD-1 and anti-PD-L1 inhibitors, whose action is 
designed to stimulate the immune system [19]. The problem is 
that only those patients who are positive for the CTLA4 protein, 
the so-called programmed death receptor 1 (PD-1) and its 
ligand (PD-L1) are eligible for such treatment. However, the 
effectiveness of microflora participation in controlling these 
activities requires further research [20].
Many studies indicate that the intestinal microflora not 
only plays a role in the formation of cancer, but also modifies 
the effectiveness of therapy [19]. Recently, research has been 
presented on the regulation of the composition and methods 
of using probiotics in patients undergoing chemotherapy and 
radiotherapy [18]. Suggestions to use the microflora as suppor-
tive treatment for other cancer therapies, such as chemothe-
rapy and immunotherapy, are also being considered [16, 17].
There are also studies that show the benefits of regulating 
the intestinal microflora through the use of probiotics in patients 
treated oncologically with 5-fluorouracil (5-FU), which is one of 
the chemotherapeutic agents used in the treatment of cancer. 
This drug significantly damages the microflora, and, therefore, 
its correction with the use of probiotics is highly desirable [21]. 
In addition to the unquestionable benefits of supra-cancer 
therapy, the use of probiotics may also cause adverse effects in 
immunocompromised patients. Attempts are being made to 
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develop the possibility of individually selecting bacterial species, 
taking into account the specific needs of each patient. That kind 
of program would allow for obtaining the beneficial effects of 
using probiotics while avoiding side effects [22, 23].
Wieczorska et al. emphasize that intestinal microbiome 
analysis can be potentially used to develop non-invasive dia-
gnostic tests. These tests could be useful as new protective 
markers for colorectal cancer, or as prognostic markers and 
predictive markers of the response to treatment, especially 
immunotherapy [24, 25].
Conclusions
At present, it is generally accepted that intestinal bacteria have 
an important influence on the cancer process. Depending 
on the composition of the microbiome, this influence may 
intensify cancer processes; however, it may also consist in 
protective functions, as well as preventing or slowing onco-
genesis when the composition of the microbiome changes. 
The research conducted shows that modifying the microbiome 
using probiotics may be beneficial in cancer therapy and may 
be used as a supportive treatment for classic cancer therapies 
such as chemotherapy, radiotherapy and surgical treatment. 
Extensive clinical trials are nonetheless required to identify 
the dosages and administration regimes as a supportive or 
alternative cancer treatment. Further work is also needed on 
re-selecting systems for the selection of optimal microbiome 
compositions for the individual needs of each patient, i.e. on 
so-called microbiological biological engineering [26].
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